Abbott Laboratories
—- Market cap
- $178.48B
- Debt
- —
- Cash
- −$8.52B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $178.48B · View financials
Snapshot Sep 11, 2026, 9:45 AM ET
Decision snapshot: ABT stock price vs STX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at STX's multiple
Needs STX P/E.
Implied fair value · at ABT's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Seagate Technology Holdings plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Johnson & Johnson
ABT vs JNJ
Medtronic plc
ABT vs MDT
BECTON DICKINSON & CO
ABT vs BDX
Thermo Fisher Scientific Inc.
ABT vs TMO
DANAHER CORP /DE/
ABT vs DHR
BOSTON SCIENTIFIC CORP
ABT vs BSX
WESTERN DIGITAL CORP
ABT vs WDC
NetApp, Inc.
ABT vs NTAP
Dell Technologies Inc.
ABT vs DELL
Hewlett Packard Enterprise Co
ABT vs HPE
QUANTUM CORP /DE/
ABT vs QMCO
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABT’s growth and quality will re-accelerate enough to justify a premium near the top of its historical band, then hold or add modestly; otherwise, reduce exposure because the current price of $107.12 is above the DCF range and ABT is not cheap on a relative basis despite operating strengths.
ABT trades at 28.8x P/E versus STX at 122.8x, but the more relevant point is that ABT still looks pricey relative to its own historical band and DCF range while STX’s valuation is distorted by much higher growth expectations. ABT’s current price of $107.12 sits near the top of its historical band ($96.41-$117.83) but far above the DCF range ($50.11-$67.80), suggesting limited margin of safety.
Supporting Metrics